N/A N=24 Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
Acute Alcohol Withdrawal
Primary: Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal — 180.5; 112.5; 109.1 mg — p=0.64
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Remote Treatment of Alcohol Withdrawal
Alcohol Withdrawal
Primary: Retention in Treatment — 28 Participants — p=0.0021
N/A N=102 Phenobarbital for Acute Alcohol Withdrawal
Alcohol Withdrawal
Primary: Number of Patients Requiring Continuous Lorazepam Infusion — 2; 16 participants
Phase 2 N=49 Acamprosate to Reduce Symptoms of Alcohol Withdrawal
Alcohol-Related Disorders · Alcohol Dependence · Alcoholism
Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine
Phase 4 N=88 Gabapentin for Alcohol Withdrawal Syndrome
Alcohol Withdrawal Syndrome
Primary: Mean Length of Hospital Stay — 44.91; 50.50 hours
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
N/A N=46 Treating Alcohol Withdrawal With Oral Baclofen
Alcohol Withdrawal Delirium
Primary: Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups — 14.1; 124.4 mg of benzodiazepine per 8 hours
Phase 4 N=26 Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
Alcohol Withdrawal
Primary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale
Phase 2 N=52 Ibudilast and Withdrawal-Related Dysphoria
Alcohol Use Disorder
Primary: Negative Affect — 2.91; 2.47 units — p=.62
N/A N=498 Delirium in the Emergency Department: Novel Screening
Delirium
Primary: Delirium — 98.0; 56.2; 56.2; 54.8 percent
Phase 4 N=248 Alcohol Disorder hOsPital Treatment Trial
Heavy Drinking · Alcohol Dependence · Alcohol Use Disorder
Primary: Change in Percent Heavy Drinking Days (%HDDs) Over the Past 30 Days From Baseline to 3 Month Follow-up, Assessed Using the Timeline Follow-Back — -46.4; -38.4 change in…
N/A N=53 Ketogenic Diet (KD) in Alcoholism
Alcoholism
Primary: Withdrawal Symptoms Measured Using the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) — 4.16; 6.57 score on a scale — p=0.067
N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Phase 3 N=75 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Bipolar Disorder · Alcoholism · Alcohol Abuse
Primary: Timeline Follow Back (TLFB) — -0.82; -0.71 drinks per drinking day
Phase 4 N=163 A Randomized Clinical Trial of Alcohol Care Management
Alcohol Dependence
Primary: Treatment Engagement — 36; 9 percentage of participants engaged
Phase 1 N=14 Oxytocin Treatment of Alcohol Withdrawal
Alcohol Withdrawal
Primary: Total Lorazepam Dosage (in Milligrams) — 16.5; 3.4 milligrams of lorazepam
N/A N=737 Determining the Preliminary Efficacy of the Emergency Department Delirium Screening and Detection Program
Delirium
Primary: Proportion of Positive Delirium Screens Among Those With Delirium — 0; 10; 0; 1 Participants
N/A N=18 Implementation Outcome Assessments of the Emergency Department Delirium Screening and Detection Program
Delirium
Primary: Accurate Delirium Screening by Emergency Department (ED) Nurses (RE-AIM: Efficacy) — 4; 1; 8 Site nurses who received Spot Check Form
Phase 4 N=60 Dexmedetomidine Versus Morphine and Midazolam in Prevention and Treatment of Delirium After Adult Cardiac Surgery
Delirium
Primary: The Incidence of Delirium (Number of Patients (in Digits)) — 1; 2 participants
Phase 2 N=50 Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Alcohol Use Disorder
Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065
Early Phase 1 N=44 Inpatient Single Dose Interventions for Alcohol Use Disorder
Alcohol Use Disorder, Severe
Primary: Rate (%) of 30-day Hospital Re-admission — 3; 2; 7 Participants
N/A N=551 Pharmacological Management of Delirium
Delirium · Cognitive Impairment
Primary: Days Free of Delirium and Coma — 4; 5; 4; 5 days
Phase 3 N=60 Prometa Protocol for Alcohol Dependence
Alcohol Dependence
Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03
N/A N=33 Alcohol Biosensor Monitoring for Alcoholic Liver Disease
Alcohol Use, Unspecified
Primary: Alcohol Use — 7.4; 5.3; 4.4 drinks per episode
Phase 3 N=672 The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial
Delirium
Primary: Number of Patients With Incidence of Delirium Across All Patients at Baseline and Over Post-operative Days 1-3 — 85; 43 Participants — p=0.912
N/A N=81 Delirium Treatment With Acupuncture in Internal Medicine Departments
Delirium in Old Age
Primary: Number of Delirium-free Days During the 7 Days of Evaluation — 5.5; 0 days — p=<0.001
Phase 1 N=26 Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Alcohol Dependence
Primary: Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo — 21; 30.4; 10.8; 10.6 score on a scale
N/A N=674 STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse
Major Depressive Disorder · Alcohol Use Disorder
Primary: Quick Inventory of Depression- Self Report 16 — 9.3; 8.9 units on a scale
N/A N=11 Effect of Theta Burst Stimulation on Alcohol Cue Reactivity
Alcohol Drinking · Alcohol Use Disorder · Trauma Injury
Primary: Behavioral Outcomes: Change in the k-Value, a Measure of Delay Discounting of Alcohol — -0.12; -7.42 Change in k-value
Phase 4 N=121 Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery
Delirium
Primary: Incidence of Delirium — 2; 4; 8; 9 Participants